AI-Powered Tempus Inks New Multi-Year Merck Deal

robot
Abstract generation in progress

Tempus AI (NASDAQ: TEM) has announced an expanded, multi-year collaboration with Merck & Co. Inc. (NYSE: MRK) to accelerate AI-driven precision medicine, focusing on discovering and developing precision medicine biomarkers. This partnership will leverage Tempus’s data and Lens Platform to support Merck’s oncology and broader therapeutic portfolios. Despite the positive news, Tempus AI shares were down due to a broader market downturn.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)